Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bakirov, Bulat
NCT06497036: Study of Efficacy, Safety and Immunogenicity of GP40141 (GEROPHARM, Russia) in Patients With Immune Thrombocytopenia	Active, not recruiting	3	160	RoW	GP404141, romiplostim, Nplate, romilostim	Geropharm, Pharm-Holding, I.M. Sechenov First Moscow State Medical University	Drug Effect, Safety Issues, Immunogenicity	03/28	03/28
DARVIVA, NCT06296121: A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma	Recruiting	3	252	RoW	BCD-264, daratumumab, Darzalex	Biocad	Multiple Myeloma	01/25	07/26
FLAMMINGO, NCT06668792: An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients with Relapsed/Refractory Multiple Myeloma	Recruiting	2	100	RoW	BCD-248	Biocad	Relapsed/Refractory Multiple Myeloma	02/26	07/28

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bakirov, Bulat
NCT06497036: Study of Efficacy, Safety and Immunogenicity of GP40141 (GEROPHARM, Russia) in Patients With Immune Thrombocytopenia	Active, not recruiting	3	160	RoW	GP404141, romiplostim, Nplate, romilostim	Geropharm, Pharm-Holding, I.M. Sechenov First Moscow State Medical University	Drug Effect, Safety Issues, Immunogenicity	03/28	03/28
DARVIVA, NCT06296121: A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma	Recruiting	3	252	RoW	BCD-264, daratumumab, Darzalex	Biocad	Multiple Myeloma	01/25	07/26
FLAMMINGO, NCT06668792: An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients with Relapsed/Refractory Multiple Myeloma	Recruiting	2	100	RoW	BCD-248	Biocad	Relapsed/Refractory Multiple Myeloma	02/26	07/28